Clinical Trial Update: A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating HY004 for adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• HY004

Snippet

Sponsor: Juventas Cell Therapy Ltd. | Conditions: B-cell Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN